Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development
S
Stephen M. Hahn
(Nucleus RadioPharma, Davidson, NC)
N
Norman E. Sharpless
(University of North Carolina, Chapel Hill)
C
Christer Svedman
(N-Power Medicine Inc, Redwood City, CA)
W
William B. Capra
(N-Power Medicine Inc, Redwood City, CA)
M
Mark Lee
M
Mark A. Socinski
Article Details
Journal
Journal of Clinical Oncology
Volume / Issue
Vol. 1, Issue 1
Published
August 05, 2026
ISSN
0732-183X
Publisher
Lippincott Williams & Wilkins
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences
Authors (6)
S
Stephen M. Hahn
Nucleus RadioPharma, Davidson, NC
N
Norman E. Sharpless
University of North Carolina, Chapel Hill
C
Christer Svedman
N-Power Medicine Inc, Redwood City, CA
W
William B. Capra
N-Power Medicine Inc, Redwood City, CA
M
Mark Lee
M
Mark A. Socinski
Related Articles from this Journal
Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Ismaela Anna Vascotto, Filippo Antonica et al.
Aug 2026
10.1200/jco-26-00658
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
Samer A. Srour, Jad Chahoud et al.
Aug 2026
10.1200/jco-26-00388
Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection
Risako Komata, Kenju Ando et al.
Aug 2026
10.1200/jco-26-00140
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
Ghayas C. Issa, Branko Cuglievan et al.
Aug 2026
10.1200/jco-26-01743
Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Irbaz Bin Riaz, R. Bryan Rumble et al.
Aug 2026
10.1200/jco-26-01001